Oslo bid for the 2022 Winter Olympics

BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®

Retrieved on: 
Thursday, December 8, 2022
HLA, Toronto Stock Exchange, JCO, BCT, DCR, Toxicity, Blood, EDGAR, FDA, Cancer, Biotechnology, PD-1, Sony DCR-TRV900, Risk, TSX, PFS, MBC, Merck, Quality of life, Mayo Clinic, News, Trial of the century, Oslo bid for the 2022 Winter Olympics, Pembrolizumab, Patient, Poster, Probability, SEDAR, Survival, Therapy, Barcode of Life Data System, Medical imaging, Pharmaceutical industry, Vaccine

“Better quality of life” and “less pain” reported by many gravely ill advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen.

Key Points: 
  • “Better quality of life” and “less pain” reported by many gravely ill advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen.
  • Quality of Life Data: Patients who experienced disease control reported “better quality of life” scores and “less pain” with the BriaCell combination regimen.
  • Found in the blood of 90% of the advanced metastatic breast cancer patients, Cancer Associated Macrophage Like cells (“CAMLs”) (Adams DL, et al.
  • BriaCell will seek to further evaluate Bria-OTS2.0’s activity in advanced metastatic breast cancer patients.

Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 2, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Ovarian cancer, Degenerative disease, IND, Breast cancer, Autoimmunity, Folate, Exatecan, Safety, Oslo bid for the 2022 Winter Olympics, Intellectual property, Neoplasm, News, Pharmacy, Cancer, Therapy, ADC, Marketing, WeChat, Stomach, Patient, Engineering, Bystander effect, Folate receptor, Fine chemical, Medical imaging, Fashion, Pharmaceutical industry

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 - 10, 2022 in San Antonio, Texas.

Key Points: 
  • Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 - 10, 2022 in San Antonio, Texas.
  • Folate Receptor is a naturally occurring receptor that is overexpressed in many types of cancer, including breast cancer and ovarian cancer.
  • Trop-2 is a naturally occurring receptor that is overexpressed in many types of cancer, including triple negative breast cancer and gastric cancer.
  • This news release contains certain forward-looking statements relating to BAT8006, BAT8008 or the product pipelines in general of Bio-Thera Solutions.

New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, VP, Itch, Angioedema, Adult, AHS, Teva, Uveitis, Contraindication, Annual report, Headache (journal), Forward-looking statement, Teva Pharmaceuticals, Migraine, Hypersensitivity, Calcitonin, Travel, Annual general meeting, MMD, Failure, TEVA, Investment, Medication, TASE, Anaphylaxis, 2021 Essex County Council election, Index, Patient, Private Securities Litigation Reform Act, Drug, NYSE, 6.5×68mm, COVID-19, Hives, Lists of diseases, Compliance, Excipient, MD, Obesity, Oslo bid for the 2022 Winter Olympics, Rash, Pharmaceutical industry, Vaccine

The data showing a reduction in monthly migraine days with the treatment combination were presented as a late-breaking poster during the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado.

Key Points: 
  • The data showing a reduction in monthly migraine days with the treatment combination were presented as a late-breaking poster during the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado.
  • Data presentations at AHS included eight abstracts examining real-world use of AJOVY across different patient populations and clinical circumstances.
  • The real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab study was also highlighted.
  • As the migraine treatment landscape continues to advance, these data provide important insights about AJOVY in real-world settings and its use as a migraine preventive treatment across a spectrum of patients.

Dermavant Presents New Patient Satisfaction Data from PSOARING 3 Long Term Extension Trial of Tapinarof in Adults with Plaque Psoriasis at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Saturday, January 15, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, People, Atopic dermatitis, Ageing, New Drug Application, Roivant Sciences, Patient, Research, Vitiligo, Week, Conference, Acne, Psoriasis, LinkedIn, Dermatitis, Perception, Inflammatory bowel disease, Safety, Adult, PGA, Patient satisfaction, QD, Obesity, Hypertension, Skin, National Psoriasis Foundation, Oslo bid for the 2022 Winter Olympics, Diabetes, Efficiency, Quality of life, Depression, Therapy, Risk, Twitter, FDA, Physician, Pharmaceutical industry, Medical device, Dermavant’s Phase 3 Program for Tapinarof in Psoriasis, Psoriasis, Dermavant, DERMAVANT’S PHASE 3 PROGRAM FOR TAPINAROF IN PSORIASIS, PSORIASIS, DERMAVANT

These results were presented during the 2022 Winter Clinical Dermatology Conference, held January 14-19 in Koloa, Hawaii.

Key Points: 
  • These results were presented during the 2022 Winter Clinical Dermatology Conference, held January 14-19 in Koloa, Hawaii.
  • Dermavants pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study.
  • PSOARING 3 was a long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults.
  • The company has reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis.